France-based Eurobio Scientific has unveiled two new proprietary tests, EBX 048, Eurobioplex SARS-CoV-2 Fast-SVT and EBX 060 Eurobioplex SARS-CoV-2 Monkeypox Screening Test.
The EBX 048 is designed specifically for routine screening of Covid-19 including Omicron BA.1, Omicron BA.2 and Omicron BA.4/BA.5 variants, while EBX 060 is developed for routine screening of simian pox, varicella and measles viruses.
The EBX SARS-CoV-2 Fast-SVT is a proprietary real-time polymerase chain reaction (RT-PCR2) assay that, in a single test, detects the K417N, S:V213G, and L452R mutations in a qualitative manner.
The presence of the three mutations distinguishes the BA.4/BA.5 sublineages from the other Omicron variant sublineages.
The EBX Monkeypox Screening Test (hMPXV, VZV, Measles) is a proprietary real-time polymerase chain reaction test that detects the presence of 3 viruses responsible for a clinical picture in a single test.
Developed by Eurobio Scientific’s R&D department, the tests are manufactured in-house facility in Les Ulis, France and follow the ISO 13485 regulatory process.
Eurobio Scientific said that the test requires only one reaction and can deliver the results in 45 minutes.
EBX SARS-CoV-2 Fast-SVT and EBX Monkeypox Screening Test (hMPXV, VZV, Measles) are now available for hospital and private laboratories in France and globally, in their CE-IVD and RUO versions, respectively.
The firm has also verified the efficacy of its proprietary EBS-1001 test for the identification of BA.4/BA.5 sub-variants in the field of quick antigenic tests.
In September 2020, the company introduced its first rapid diagnostic test to detect the SARS CoV-2 virus antigen.
